VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CLDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CLDXCelldex Therapeutics, Inc.
$29.87$2.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCLDXQuarterly Financials

Celldex Therapeutics, Inc. (CLDX) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Celldex Therapeutics, Inc. (CLDX) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

CLDX Income Statement

Quarterly statement

CLDX Income Statement

Celldex Therapeutics, Inc. (CLDX) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21
Sales/Revenue022K15K75K0730K695K1.18M3.19M2.5M156K4.13M1.52M268K967K1.61M407K163K174K334K
Revenue Growth %--96.99%-97.84%-93.62%-100%-70.78%345.51%-71.56%110.35%832.09%-83.87%156.11%272.73%64.42%455.75%382.93%166.01%-95.32%-74.6%-91.18%
Cost of Goods Sold82.25M0854K062.93M54.2M52.61M819K45.26M797K775K30.43M767K26.25M26.8M22.9M21.57M20.73M17.06M14.68M
COGS % of Revenue--5693.33%--7424.11%7570.36%69.7%1418.46%31.91%496.79%736.53%50.56%9795.52%2771.25%1419.65%5300.25%12718.4%9802.3%4394.61%
Gross Profit-82.25M22K-839K75K-62.93M-53.47M-51.92M356K-42.07M1.7M-619K-26.3M750K-25.98M-25.83M-21.29M-21.16M-20.57M-16.88M-14.34M
Gross Margin %-100%-5593.33%100%--7324.11%-7470.36%30.3%-1318.46%68.09%-396.79%-636.53%49.44%-9695.52%-2671.25%-1319.65%-5200.25%-12618.4%-9702.3%-4294.61%
Gross Profit Growth %-30.7%100.04%98.38%-78.93%-49.58%-3243.21%-8287.56%101.35%-5709.6%106.55%97.6%-23.53%103.54%-26.33%-53.01%-48.4%-57.9%-131.73%-40.27%-116.02%
Operating Expenses82.25M80.64M83.6M87.26M10.69M10.39M10.82M56.38M10.05M48.02M39.99M21.33M41.99M7.22M6.64M6.6M6.53M15.83M6.38M6M
OpEx % of Revenue-366568.18%557306.67%116349.33%-1423.42%1556.83%4798.55%315.07%1922.26%25633.97%516.39%2767.9%2694.4%686.66%409.11%1604.67%9710.43%3663.79%1795.21%
Selling, General & Admin14.84M13.1M11.45M11.9M10.69M10.39M10.82M10.26M10.05M9.13M9.1M8.83M8.22M7.22M6.64M6.6M6.53M7.15M6.91M6.24M
SG&A % of Revenue-59559.09%76326.67%15870.67%-1423.42%1556.83%873.45%315.07%365.41%5835.26%213.8%541.92%2694.4%686.66%409.11%1604.67%4388.96%3971.84%1868.56%
Research & Development67.41M67.55M73M75.36M62.93M54.2M52.61M46.12M45.26M38.89M30.89M30.43M34.53M26.25M26.8M22.9M21.57M20.73M17.06M14.68M
R&D % of Revenue-307040.91%486673.33%100478.67%-7424.11%7570.36%3925.11%1418.46%1556.85%19798.72%736.53%2276.53%9795.52%2771.25%1419.65%5300.25%12718.4%9802.3%4394.61%
Other Operating Expenses0-7K-854K0-1000K-1000K-1000K0-1000K00-1000K-767K-1000K-1000K-1000K-1000K-1000K-1000K-1000K
Operating Income-82.25M-80.62M-84.44M-87.19M-73.62M-63.86M-62.74M-56.03M-52.13M-46.32M-40.61M-47.63M-41.24M-33.2M-32.47M-27.89M-27.7M-36.4M-23.26M-20.34M
Operating Margin %--366468.18%-562900%-116249.33%--8747.53%-9027.19%-4768.26%-1633.53%-1854.16%-26030.77%-1152.92%-2718.46%-12389.93%-3357.91%-1728.77%-6804.91%-22328.83%-13366.09%-6089.82%
Operating Income Growth %-11.73%-26.26%-34.58%-55.62%-41.23%-37.87%-54.5%-17.64%-26.4%-39.49%-25.06%-70.8%-48.9%8.77%-39.62%-37.09%-33%-170.8%-39.77%17.92%
EBITDA-81.09M-79.72M-83.58M-86.37M-72.79M-62.98M-61.87M-55.21M-51.34M-45.52M-39.83M-46.87M-40.47M-32.45M-31.75M-27.21M-27.02M-35.66M-22.45M-19.56M
EBITDA Margin %--362368.18%-557206.67%-115161.33%--8627.95%-8902.45%-4698.55%-1608.9%-1822.26%-25533.97%-1134.54%-2667.9%-12107.84%-3282.83%-1687.04%-6640.05%-21874.23%-12900%-5857.19%
EBITDA Growth %-11.4%-26.57%-35.09%-56.45%-41.79%-38.37%-55.33%-17.79%-26.85%-40.28%-25.48%-72.23%-49.76%8.99%-41.43%-39.1%-34.64%-181.28%-41.49%18.58%
D&A (Non-Cash Add-back)1.16M902K854K816K824K873K867K819K786K797K775K759K767K756K726K673K671K741K811K777K
EBIT-75.56M-73.5M-78.69M-81.36M-67.04M-56.6M-53.8M-47.09M-42.12M-35.84M-32.81M-35.13M-41.24M-33.2M-32.47M-27.89M-27.7M-27.72M-23.79M-20.59M
Net Interest Income07.12M5.75M5.84M6.57M7.26M8.94M8.94M10.01M10.47M7.8M1.21M2.98M2.7M3.11M1.4M912K392K207K192K
Interest Income07.12M5.75M5.84M6.57M7.26M8.94M8.94M10.01M10.47M7.8M4.32M2.98M2.7M3.11M1.4M912K392K207K192K
Interest Expense000000000003.11M00000000
Other Income/Expense6.69M7.12M5.75M5.83M6.57M7.26M8.94M8.94M10.01M10.47M7.8M4.32M2.98M2.7M3.11M1.4M912K392K207K192K
Pretax Income-75.56M-73.5M-78.69M-81.36M-67.04M-56.6M-53.8M-47.09M-42.12M-35.84M-32.81M-43.31M-38.26M-30.5M-29.36M-26.49M-26.78M-36M-23.05M-20.15M
Pretax Margin %--334104.55%-524566.67%-108480%--7753.42%-7740.43%-4007.83%-1319.99%-1434.83%-21030.77%-1048.32%-2522.08%-11381.34%-3036.3%-1642.1%-6580.84%-22088.34%-13247.13%-6032.34%
Income Tax00000000000000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%
Net Income-75.56M-73.5M-78.69M-81.36M-67.04M-56.6M-53.8M-47.09M-42.12M-35.84M-32.81M-43.31M-38.26M-30.5M-29.36M-26.49M-26.78M-36M-23.05M-20.15M
Net Margin %--334104.55%-524566.67%-108480%--7753.42%-7740.43%-4007.83%-1319.99%-1434.83%-21030.77%-1048.32%-2522.08%-11381.34%-3036.3%-1642.1%-6580.84%-22088.34%-13247.13%-6032.34%
Net Income Growth %-12.7%-29.86%-46.27%-72.77%-59.17%-57.92%-63.97%-8.74%-10.09%-17.51%-11.74%-63.5%-42.85%15.28%-27.38%-31.46%-30.96%-169.23%-39.38%8%
Net Income (Continuing)-75.56M-73.5M-78.69M-81.36M-67.04M-56.6M-53.8M-47.09M-42.12M-35.84M-32.81M-43.31M-38.26M-30.5M-29.36M-26.49M-26.78M-36M-23.05M-20.15M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-0.96-0.94-1.18-1.23-1.01-0.85-0.81-0.71-0.64-0.54-0.56-0.83-0.81-0.65-0.62-0.56-0.57-0.77-0.49-0.43
EPS Growth %4.95%-10.59%-45.68%-73.24%-57.81%-57.41%-44.64%14.46%20.99%16.92%9.68%-48.21%-42.11%15.58%-26.53%-30.23%-26.67%-126.47%-16.67%21.82%
EPS (Basic)-0.96-0.94-1.18-1.23-1.01-0.85-0.81-0.71-0.64-0.54-0.56-0.83-0.81-0.65-0.62-0.56-0.57-0.77-0.49-0.43
Diluted Shares Outstanding78.53M77.84M66.57M66.5M66.42M66.39M66.38M66.35M66.29M66.02M58.87M52.03M47.26M47.25M47.21M47.13M46.92M46.76M46.74M46.69M
Basic Shares Outstanding78.53M77.84M66.57M66.5M66.42M66.39M66.38M66.35M66.29M66.02M58.87M52.03M47.26M47.25M47.21M47.13M46.92M46.76M46.74M46.58M
Dividend Payout Ratio--------------------